Yahoo Finance

Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss

Spark Therapeutics, Inc. ONCE announced that the European Commission (“EC”) has approved the marketing authorization application (“MAA”) for its gene therapy, Luxturna (voretigene neparvovec). The MAA ...
PharmaTimes

Novartis buys access to Spark’s vision loss therapy

Novartis has bought itself rights to Spark Therapeutic’s gene therapy for a certain type of vision loss, in a deal worth up to $170 million. Novartis has bought itself rights to Spark Therapeutic’s ...
Reuters

Spark gene therapy improves vision, at least in short term: FDA

(Reuters) - Spark Therapeutics Inc's experimental gene therapy for a rare inherited form of blindness improves vision, though it is unclear whether the benefit lasts over time, according to a ...
techtimes

Spark Therapeutics Gene Therapy Shows Promise In Restoring Vision Of Visually Impaired Patients

Spark Therapeutics announced on Monday, Oct. 5 that its experimental gene therapy called SPK-RPE65 exhibited positive results in its phase 3 clinical trial. The findings now show promise in restoring ...
MarketWatch

Novartis, Spark in vision-loss gene therapy deal

Novartis AG (NOVN.EB) has reached a licensing agreement with Spark Therapeutics Inc. ONCE to commercialize outside the U.S. a gene therapy for a form of vision loss, the companies said on Wednesday.